Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.

被引：0
|
作者：
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
DiSimone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett V.
Kubiak, Peter
Okpara, Chinyere
Smith, Alan D.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, Dept Med, Oncol Div, St Louis, MO 63110 USA
[4] South Texas Accelerated Res Therapeut, Dept Clin Res, San Antonio, TX USA
[5] Hosp Univ La Paz, Serv Oncol, Madrid, Spain
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] US Oncol Res, Rocky Mt Canc Ctr, Med Oncol, Denver, CO USA
[8] Arizona Oncol Associates, Med Oncol Hematol, Tucson, AZ USA
[9] New York Oncol Hematol, US Oncol Res, Med Oncol, Albany, NY USA
[10] Hosp Univ & Politecn FE, Med Oncol Serv, Valencia, Spain
[11] Sorlandet Hosp Kristiansand, Med Oncol, Kristiansand, Norway
[12] Eisai Inc, Biostat, Woodcliff Lake, NJ USA
[13] Merck & Co Inc, Clin Res, Kenilworth, NJ USA
[14] Eisai Inc, Clin Res, Woodcliff Lake, NJ USA
[15] Eisai Ltd, Clin Res, Hatfield, Herts, England
[16] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
    Motzer, Robert J.
    Choueiri, Toni K.
    Hutson, Thomas
    Rha, Sun Young
    Puente, Javier
    Lalani, Aly-Khan A.
    Winquist, Eric
    Eto, Masatoshi
    Basappa, Naveen S.
    Tannir, Nizar M.
    Vaishampayan, Ulka
    Bjarnason, Georg A.
    Oudard, Stephane
    Gruenwald, Viktor
    Burgents, Joseph
    Xie, Ran
    McKenzie, Jodi
    Powles, Thomas
    EUROPEAN UROLOGY, 2024, 86 (01) : 4 - 9
  • [42] Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Rao, Arpit
    Taylor, Matthew H.
    Di Simone, Christopher
    Hsieh, James J.
    Pinto, Alvaro
    Sarrio, Regina Girones
    Cohn, Allen Lee
    Bilen, Mehmet Asim
    Ribe, Sara Gunnestad
    Tennoe, Oyvind Krohn
    Richards, Donald
    Sweis, Randy F.
    Courtright, Jay
    Heinrich, Daniel
    Perini, Rodolfo
    Kubiak, Peter
    Bock, Daena
    Okpara, Chinyere E.
    Motzer, Robert J.
    EUROPEAN UROLOGY, 2024, 86 (05) : 470 - 473
  • [43] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma
    Hutson, Thomas
    Xing, Dongyuan
    Dutcus, Corina
    Baig, Mahadi
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 14 - 15
  • [44] Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.
    Choueiri, Toni K.
    Hodi, F. Stephen
    Thompson, John A.
    McDermott, David F.
    Hwu, Wen-Jen
    Lawrence, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [45] A phase Ib study of lenvatinib plus pembrolizumab (LEN plus PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
    Kudo, M.
    Finn, R.
    Ikeda, M.
    Zhu, A.
    Sung, M.
    Baron, A.
    Okusaka, T.
    Kobayashi, M.
    Kumada, H.
    Kaneko, S.
    Pracht, M.
    Meyer, T.
    Nagao, S.
    Saito, K.
    Mody, K.
    Dubrovsky, L.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1402
  • [46] Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
    Gruenwald, V.
    Mckay, R. R.
    Buchler, T.
    Eto, M.
    Park, S. H.
    Takagi, T.
    Zanetta, S.
    Keizman, D.
    Suarez Rodriguez, C.
    Negrier, S.
    Lee, J-L.
    Santini, D.
    Bedke, J.
    Staehler, M.
    Kollmannsberger, C. K.
    Choueiri, T. K.
    Motzer, R. J.
    Burgents, J.
    Okpara, C. E.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1024 - S1025
  • [47] Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial.
    Keizman, Daniel
    Bedke, Jens
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Saal, Hakim
    Choueiri, Toni K.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 531 - 531
  • [48] Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study
    Eggermont, A. M. M.
    Carlino, M. S.
    Hauschild, A.
    Ascierto, P. A.
    Arance, A.
    Daud, A.
    O'Day, S. J.
    Taylor, M. H.
    Smith, A.
    Rodgers, A.
    Moreno, B. Homet
    Diede, S. J.
    Kluger, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC)
    Choueiri, T. K.
    Plimack, E. R.
    Gupta, S.
    Cho, D.
    Hutson, T. E.
    Puzanov, I.
    George, S.
    Olencki, T.
    Vaishampayan, U.
    Chakrabarti, D.
    Pithavala, Y. K.
    Williams, J. A.
    Rosbrook, B.
    Tarazi, J. C.
    Atkins, M. B.
    BJU INTERNATIONAL, 2014, 114 : 4 - 5
  • [50] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Gruenwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas
    Motzer, Robert
    Winquist, Eric
    Maroto, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan
    Porta, Camillo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 104 - 105
12345